SCHEMBL24104675

SCHEMBL24104675

COc1ccc(-c2cnc3c(Nc4ccc(NC(=O)CN5CCNCC5)c(C)c4)nccn23)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTK6 Q13882 11/20 0.50
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ EGFR P00533 1/20 0.44
▸ PTK2 Q05397 1/20 0.44
▸ AURKB Q96GD4 3/20 0.42
▸ LCK P06239 3/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KDR P35968 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ BCL6 P41182 1/20 0.40
▸ MAP4K1 Q92918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24105192 0.90 PTK6 (0.47) PTK6KMT2AALDH1A1MEN1EGFR
SCHEMBL30371857 0.86 PTK6 (0.46) PTK6EGFRKDR
SCHEMBL25447277 0.86 PTK6 (0.46) PTK6EGFRKDR
SCHEMBL24105205 0.83 KDR (0.48) PTK6KMT2AALDH1A1MEN1EGFR
SCHEMBL24104669 0.80 PAX8 (0.43) PTK6AURKBLMNA
SCHEMBL30168157 0.80 PTK6 (0.49) PTK6EGFRLCKKDR
SCHEMBL24105229 0.80 PTK6 (0.49) PTK6EGFRLCKKDR
SCHEMBL22122857 0.80 PTK6 (0.49) PTK6ALDH1A1
Hydrochloric Acid SCHEMBL30171816 0.79 PTK6 (0.49) PTK6ALDH1A1
SCHEMBL25167794 0.79 PTK6 (0.46) PTK6KMT2AALDH1A1MEN1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US claimed
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
CN-115667264-A Novel imidazo-pyrazine derivatives 豪夫迈·罗氏有限公司 2023-01-31 — — CN disclosed
WO-2021249893-A1 NOVEL IMIDAZO-PYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES XDH, MYD88, IKZF3 PTK6 2213/4885KMT2A 3088/4885ALDH1A1 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback